Back to results
US 10,946,106 B2Granted
Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
AssigneeThe Regents of the University of California
InventorsBin Liu, Scott Bidlingmaier, Yang Su
Life of this patent
Estimating the term…
Abstract
This invention provides antibodies directed against a highly specific and previously unrecognized marker for cancerous cells. In certain embodiments an isolated antibody or fragment thereof that specifically binds human placentally expressed ALPP and/or ALPPL2, but not ALPL and ALPI that are expressed outside the placenta is provided as well as immunoconjugates comprising such antibodies.
Claims11
An isolated antibody that binds human placentally expressed ALPP and/or ALPPL2, but not ALPL and ALPI that are expressed outside the placenta wherein:
- said antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), where:
- said heavy chain variable region comprises a variable heavy M25FYIA antibody CDR1 comprising the amino acid sequence GFTFSSYA (residues 26-33 of SEQ ID NO:6), a variable heavy M25FYIA antibody CDR2 comprising the amino acid sequence ISYDGSNK (residues 51-58 of SEQ ID NO:6, and a variable heavy M25FYIA antibody CDR3 comprising the amino acid sequence AKEGDSSRWSYDL (residues 97-109 of SEQ ID NO:6);
- and
- said light chain variable region comprises a variable light M25FYIA antibody CDR1 comprising the amino acid sequence SSDVGGYNY (residues 161-169 of SEQ ID NO:6), a variable light M25FYIA antibody CDR2 comprising the amino acid sequence DVT (residues 187-189 of SEQ ID NO:6), and a variable light M25FYIA antibody CDR3 consisting of the amino acid sequence SSYTIASTLVV (residues 226-236 of SEQ ID NO:6).
1 more element
Dependencies are inferred from the claim text.